Professional Documents
Culture Documents
Alston
4-25-17
Continue the use of the clinical-pathologic template for Hodgkin Lymphomas. (he said non?)
Reed-Sternberg cells RS are characteristic of Hodgkin’s disease
(HD) and arise from B-cells germinal center
CD15 and CD30 positive (except lymphocyte predominance)
Negative for leukocyte common antigen (CD45)
RS cells induce accumulation of lymphocytes, macrophages, and
granulocytes
HD starts in single node or chainspreads in stepwise fashion
o Unique from other lymphomas
EBV present in some RS cells
o 70% of mixed cellularity type
Surrounding inflammatory infiltrate that plays active role in production
of growth factors
Various cytokines produced by tumor (ex. NF-kB)
Hodgkin lymphoma cardinal example of tumor that escapes from host immune response by expressing proteins
that inhibit T cell function (classical due high PD
ligandsantagonize T cell responses)
Clinical
Painless lymphadenopathy
Staging is VERY important for TTX and prognosis (pg. 3)
Stage I and II:
o Young pts w/ less extensive disease
o favorable subtypes (nodular sclerosis and lymphocyte
predominance)
o Stage I and Ia have 90% of 5 year survival
Advanced disease: more likely to have systemic complications
o 60-70% survival
o Use anti CD 30 treatment here
Adverse factors: males, mixed cellularity or lymphocyte-depleted, advanced A. Diagnostic RS cell w/ 2
disease, constitutional symptoms, bulky tumor w/ multiple nodes involved nuclear lobes, large inclusion
COMMON SIGN: disease spreads to contiguous nodes and chains early like nucleoli, abundant
Stereotyped spread: starts in nodesmoves to spleen, hepaticfinally in cytoplasm, surrounded by
marrow and other tissues lymphocytes, macrophages, and
eosinophils.
Treatments: include chemo and radiation together
B. RS cell; mononuclear variant.
o Genotoxic chemotherapeutic agents are minimized to reduce
C. RS cell, lacunar variant.
secondary tumors
D. RS cell, lymphohistiocytic
o Anti-CD30 antibodies used
variant.
Compare and contrast (e.g. construct a table) Hodgkin Disease vs. Non-
Hodgkin Lymphomas.